Similar articles

• [Results of a cooperative programme of profilactic treatment for haemophilia A and B (author's transl)].

  [No authors listed] [No authors listed] Sangre (Barc). 1978;23(5B):780-92. Sangre (Barc). 1978. PMID: 725718 Spanish. No abstract available.
• The use of purified clotting factor concentrates in hemophilia. Influence of viral safety, cost, and supply on therapy.

  Pierce GF, Lusher JM, Brownstein AP, Goldsmith JC, Kessler CM. Pierce GF, et al. JAMA. 1989 Jun 16;261(23):3434-8. JAMA. 1989. PMID: 2498537 Review.
• [Hemophiliacs with HIV. Slower progression of the infection among younger patients and at higher dosages of factor concentrates].

  Astermark J, Berntorp E, Stigendal L, Johnsson H. Astermark J, et al. Lakartidningen. 1998 Jan 7;95(1-2):48-50. Lakartidningen. 1998. PMID: 9458646 Swedish.
• Update: acquired immunodeficiency syndrome (AIDS) in persons with hemophilia.

  Centers for Disease Control (CDC). Centers for Disease Control (CDC). MMWR Morb Mortal Wkly Rep. 1984 Oct 26;33(42):589-91. MMWR Morb Mortal Wkly Rep. 1984. PMID: 6434934 No abstract available.
• Hemophilia gene transfer: comparison with conventional protein replacement therapy.

  Ragni MV. Ragni MV. Semin Thromb Hemost. 2004 Apr;30(2):239-47. doi: 10.1055/s-2004-825637. Semin Thromb Hemost. 2004. PMID: 15118935 Review.